Immunological evaluation of the new stable ultrasound contrast agent LK565: a phase one clinical trial

BACKGROUND: Ultrasound contrast agents (UCAs) allow the enhancement of vascular definition, thereby providing more diagnostic information. LK565 is a new second-generation UCA based on synthetic polymers of aspartic acid which is eliminated from the blood stream via phagocytosis. LK565 forms very st...

Descripción completa

Detalles Bibliográficos
Autores principales: Funke, B, Maerz, HK, Okorokow, S, Polata, S, Lehmann, I, Sack, U, Wild, P, Geisler, T, Zotz, RJ
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC520823/
https://www.ncbi.nlm.nih.gov/pubmed/15357870
http://dx.doi.org/10.1186/1476-7120-2-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC520823/
https://www.ncbi.nlm.nih.gov/pubmed/15357870
http://dx.doi.org/10.1186/1476-7120-2-16

Ejemplares similares